247 related articles for article (PubMed ID: 32416631)
1. Liver Transplantation Following Yttrium-90 Radioembolization: 15-Year Experience in 207-Patient Cohort.
Gabr A; Kulik L; Mouli S; Riaz A; Ali R; Desai K; Mora RA; Ganger D; Maddur H; Flamm S; Boike J; Moore C; Thornburg B; Alasadi A; Baker T; Borja-Cacho D; Katariya N; Ladner DP; Caicedo JC; Lewandowski RJ; Salem R
Hepatology; 2021 Mar; 73(3):998-1010. PubMed ID: 32416631
[TBL] [Abstract][Full Text] [Related]
2. Comparative study of post-transplant outcomes in hepatocellular carcinoma patients treated with chemoembolization or radioembolization.
Gabr A; Abouchaleh N; Ali R; Vouche M; Atassi R; Memon K; Asadi AA; Baker T; Caicedo JC; Desai K; Fryer J; Hickey R; Abeccassis M; Habib A; Hohlastos E; Ganger D; Kulik L; Lewandowski RJ; Riaz A; Salem R
Eur J Radiol; 2017 Aug; 93():100-106. PubMed ID: 28668402
[TBL] [Abstract][Full Text] [Related]
3. Yttrium-90 radioembolization as a bridge to liver transplantation: a single-institution experience.
Tohme S; Sukato D; Chen HW; Amesur N; Zajko AB; Humar A; Geller DA; Marsh JW; Tsung A
J Vasc Interv Radiol; 2013 Nov; 24(11):1632-8. PubMed ID: 24160821
[TBL] [Abstract][Full Text] [Related]
4. Radioembolization Super Survivors: Extended Survival in Non-operative Hepatocellular Carcinoma.
Gordon AC; Gabr A; Riaz A; Uddin OM; Abouchaleh N; Ali R; Kallini J; Salem R; Lewandowski RJ
Cardiovasc Intervent Radiol; 2018 Oct; 41(10):1557-1565. PubMed ID: 29948005
[TBL] [Abstract][Full Text] [Related]
5. Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000-patient 15-year experience.
Salem R; Gabr A; Riaz A; Mora R; Ali R; Abecassis M; Hickey R; Kulik L; Ganger D; Flamm S; Atassi R; Atassi B; Sato K; Benson AB; Mulcahy MF; Abouchaleh N; Asadi AA; Desai K; Thornburg B; Vouche M; Habib A; Caicedo J; Miller FH; Yaghmai V; Kallini JR; Mouli S; Lewandowski RJ
Hepatology; 2018 Oct; 68(4):1429-1440. PubMed ID: 29194711
[TBL] [Abstract][Full Text] [Related]
6. Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study.
Salem R; Johnson GE; Kim E; Riaz A; Bishay V; Boucher E; Fowers K; Lewandowski R; Padia SA
Hepatology; 2021 Nov; 74(5):2342-2352. PubMed ID: 33739462
[TBL] [Abstract][Full Text] [Related]
7. Yttrium-90 Radioembolization for Hepatocellular Carcinoma Prior to Liver Transplantation.
Ettorre GM; Levi Sandri GB; Laurenzi A; Colasanti M; Meniconi RL; Lionetti R; Santoro R; Lepiane P; Sciuto R; Pizzi G; Cianni R; Golfieri R; D'Offizi G; Pellicelli AM; Antonini M; Vennarecci G
World J Surg; 2017 Jan; 41(1):241-249. PubMed ID: 27495316
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcomes of hepatocellular carcinoma that underwent chemoembolization for bridging or downstaging.
Affonso BB; Galastri FL; da Motta Leal Filho JM; Nasser F; Falsarella PM; Cavalcante RN; de Almeida MD; Felga GEG; Valle LGM; Wolosker N
World J Gastroenterol; 2019 Oct; 25(37):5687-5701. PubMed ID: 31602168
[TBL] [Abstract][Full Text] [Related]
9. Yttrium-90 Radioembolization for BCLC Stage C Hepatocellular Carcinoma Comparing Child-Pugh A Versus B7 Patients: Are the Outcomes Equivalent?
Zu Q; Schenning RC; Jahangiri Y; Tomozawa Y; Kolbeck KJ; Kaufman JA; Al-Hakim R; Naugler WE; Nabavizadeh N; Kardosh A; Billingsley KG; Mayo SC; Orloff SL; Enestvedt KK; Maynard E; Ahn J; Lhewa D; Farsad K
Cardiovasc Intervent Radiol; 2020 May; 43(5):721-731. PubMed ID: 32140840
[TBL] [Abstract][Full Text] [Related]
10. Morphological features of advanced hepatocellular carcinoma as a predictor of downstaging and liver transplantation: an intention-to-treat analysis.
Barakat O; Wood RP; Ozaki CF; Ankoma-Sey V; Galati J; Skolkin M; Toombs B; Round M; Moore W; Mieles L
Liver Transpl; 2010 Mar; 16(3):289-99. PubMed ID: 20209588
[TBL] [Abstract][Full Text] [Related]
11. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization.
Lewandowski RJ; Kulik LM; Riaz A; Senthilnathan S; Mulcahy MF; Ryu RK; Ibrahim SM; Sato KT; Baker T; Miller FH; Omary R; Abecassis M; Salem R
Am J Transplant; 2009 Aug; 9(8):1920-8. PubMed ID: 19552767
[TBL] [Abstract][Full Text] [Related]
12. Predictors of Successful Yttrium-90 Radioembolization Bridging or Downstaging in Patients with Hepatocellular Carcinoma.
Villalobos A; Wagstaff W; Guo M; Zhang J; Bercu Z; Whitmore MJ; Cristescu MM; Majdalany BS; Wedd J; Akce M; Magliocca J; Kokabi N
Can J Gastroenterol Hepatol; 2021; 2021():9926704. PubMed ID: 34336728
[TBL] [Abstract][Full Text] [Related]
13. Downstaging Outcomes for Hepatocellular Carcinoma: Results From the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) Consortium.
Mehta N; Frenette C; Tabrizian P; Hoteit M; Guy J; Parikh N; Ghaziani TT; Dhanasekaran R; Dodge JL; Natarajan B; Holzner ML; Frankul L; Chan W; Fobar A; Florman S; Yao FY
Gastroenterology; 2021 Nov; 161(5):1502-1512. PubMed ID: 34331914
[TBL] [Abstract][Full Text] [Related]
14. Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation.
Kulik LM; Atassi B; van Holsbeeck L; Souman T; Lewandowski RJ; Mulcahy MF; Hunter RD; Nemcek AA; Abecassis MM; Haines KG; Salem R
J Surg Oncol; 2006 Dec; 94(7):572-86. PubMed ID: 17048240
[TBL] [Abstract][Full Text] [Related]
15. Transplantation vs resection for hepatocellular carcinoma with compensated liver function after downstaging therapy.
Lei JY; Yan LN; Wang WT
World J Gastroenterol; 2013 Jul; 19(27):4400-8. PubMed ID: 23885153
[TBL] [Abstract][Full Text] [Related]
16. Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma.
Salem R; Gordon AC; Mouli S; Hickey R; Kallini J; Gabr A; Mulcahy MF; Baker T; Abecassis M; Miller FH; Yaghmai V; Sato K; Desai K; Thornburg B; Benson AB; Rademaker A; Ganger D; Kulik L; Lewandowski RJ
Gastroenterology; 2016 Dec; 151(6):1155-1163.e2. PubMed ID: 27575820
[TBL] [Abstract][Full Text] [Related]
17. Impact of Genomic Mutation and Timing of Y90 Radioembolization in Colorectal Liver Metastases.
Dabrowiecki A; Sankhla T; Shinn K; Bercu ZL; Ermentrout M; Shaib W; Cardona K; Newsome J; Kokabi N
Cardiovasc Intervent Radiol; 2020 Jul; 43(7):1006-1014. PubMed ID: 32367230
[TBL] [Abstract][Full Text] [Related]
18. Long-Term Outcome After Liver Transplantation for Hepatocellular Carcinoma Following Yttrium-90 Radioembolization Bridging Treatment.
Radunz S; Treckmann J; Baba HA; Best J; Müller S; Theysohn JM; Paul A; Benkö T
Ann Transplant; 2017 Apr; 22():215-221. PubMed ID: 28408731
[TBL] [Abstract][Full Text] [Related]
19. Response Assessment by Volumetric Iodine Uptake Measurement: Preliminary Experience in Patients with Intermediate-Advanced Hepatocellular Carcinoma Treated with Yttrium-90 Radioembolization.
Bargellini I; Crocetti L; Turini FM; Lorenzoni G; Boni G; Traino AC; Caramella D; Cioni R
Cardiovasc Intervent Radiol; 2018 Sep; 41(9):1373-1383. PubMed ID: 29654507
[TBL] [Abstract][Full Text] [Related]
20. Post-transplant infection improves outcome of hepatocellular carcinoma patients after orthotopic liver transplantation.
Chao JS; Zhao SL; Ou-Yang SW; Qian YB; Liu AQ; Tang HM; Zhong L; Peng ZH; Xu JM; Sun HC
World J Gastroenterol; 2019 Oct; 25(37):5630-5640. PubMed ID: 31602163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
